According to European Commission, if a biotech company crosses two plants to create a new plant through natural means, the outcome will not be patentable. Jane Wainwright of Potter Clarkson explains this in a video interview with Life Sciences Intellectual Property Review (LSIPR).
In this video, Wainwright discusses the commission’s review of the biotech directive and the implications of its opinion on plant patentability.
To view the video, please click here.
